Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.

Coussy F, Lavigne M, de Koning L, Botty RE, Nemati F, Naguez A, Bataillon G, Ouine B, Dahmani A, Montaudon E, Painsec P, Chateau-Joubert S, Laetitia F, Larcher T, Vacher S, Chemlali W, Briaux A, Melaabi S, Salomon AV, Guinebretiere JM, Bieche I, Marangoni E.

Theranostics. 2020 Jan 1;10(4):1531-1543. doi: 10.7150/thno.36182. eCollection 2020.

2.

Correction: Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration.

Grau MB, Masson C, Gadadhar S, Rocha C, Tort O, Sousa PM, Vacher S, Bieche I, Janke C.

J Cell Sci. 2020 Feb 10;133(3). pii: jcs244475. doi: 10.1242/jcs.244475. No abstract available.

PMID:
32041894
3.

ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin.

Tanaka I, Chakraborty A, Saulnier O, Benoit-Pilven C, Vacher S, Labiod D, Lam EWF, Bièche I, Delattre O, Pouzoulet F, Auboeuf D, Vagner S, Dutertre M.

Nucleic Acids Res. 2020 Jan 16. pii: gkz1213. doi: 10.1093/nar/gkz1213. [Epub ahead of print]

PMID:
31943118
4.

Valproic Acid Decreases Endothelial Colony Forming Cells Differentiation and Induces Endothelial-to-Mesenchymal Transition-like Process.

Nevo N, Lecourt S, Bièche I, Kucia M, Cras A, Blandinieres A, Vacher S, Gendron N, Guerin CL, Ratajczak MZ, Smadja DM.

Stem Cell Rev Rep. 2020 Jan 2. doi: 10.1007/s12015-019-09950-y. [Epub ahead of print]

PMID:
31898801
5.

Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas.

Morel A, Neuzillet C, Wack M, Lameiras S, Vacher S, Deloger M, Servant N, Veyer D, Péré H, Mariani O, Baulande S, Rouzier R, Kamal M, El Alam E, Jeannot E, Nicolas A, Bièche I, Cacheux W.

Cancers (Basel). 2019 Nov 22;11(12). pii: E1846. doi: 10.3390/cancers11121846.

6.

Prospective validation in epithelial tumors of a gene expression predictor of liver metastasis derived from uveal melanoma.

Tsantoulis P, Delorenzi M, Bièche I, Vacher S, Mariani P, Cassoux N, Houy A, Stern MH, Roman-Roman S, Dietrich PY, Roth A, Cacheux W.

Sci Rep. 2019 Nov 20;9(1):17178. doi: 10.1038/s41598-019-52841-y.

7.

P-cadherin-induced decorin secretion is required for collagen fiber alignment and directional collective cell migration.

Le Borgne-Rochet M, Angevin L, Bazellières E, Ordas L, Comunale F, Denisov EV, Tashireva LA, Perelmuter VM, Bièche I, Vacher S, Plutoni C, Seveno M, Bodin S, Gauthier-Rouvière C.

J Cell Sci. 2019 Nov 8;132(21). pii: jcs233189. doi: 10.1242/jcs.233189.

PMID:
31604795
8.

Immune gene expression in head and neck squamous cell carcinoma patients.

Lecerf C, Kamal M, Vacher S, Chemlali W, Schnitzler A, Morel C, Dubot C, Jeannot E, Meseure D, Klijanienko J, Mariani O, Borcoman E, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Choussy O, Hoffmann C, Piaggio E, Bieche I, Le Tourneau C.

Eur J Cancer. 2019 Nov;121:210-223. doi: 10.1016/j.ejca.2019.08.028. Epub 2019 Oct 5.

PMID:
31593831
9.

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.

Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M.

Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5.

PMID:
31593830
10.

PLEKHS1: A new molecular marker predicting risk of progression of non-muscle-invasive bladder cancer.

Pignot G, Le Goux C, Vacher S, Schnitzler A, Radvanyi F, Allory Y, Lallemand F, Delongchamps NB, Zerbib M, Terris B, Damotte D, Bieche I.

Oncol Lett. 2019 Oct;18(4):3471-3480. doi: 10.3892/ol.2019.10706. Epub 2019 Aug 2.

11.

High Positive Correlations between ANRIL and p16-CDKN2A/p15-CDKN2B/p14-ARF Gene Cluster Overexpression in Multi-Tumor Types Suggest Deregulated Activation of an ANRIL-ARF Bidirectional Promoter.

Drak Alsibai K, Vacher S, Meseure D, Nicolas A, Lae M, Schnitzler A, Chemlali W, Cros J, Longchampt E, Cacheux W, Pignot G, Callens C, Pasmant E, Allory Y, Bieche I.

Noncoding RNA. 2019 Aug 21;5(3). pii: E44. doi: 10.3390/ncrna5030044.

12.

Durum Wheat Stress Tolerance Induced by Endophyte Pantoea agglomerans with Genes Contributing to Plant Functions and Secondary Metabolite Arsenal.

Cherif-Silini H, Thissera B, Bouket AC, Saadaoui N, Silini A, Eshelli M, Alenezi FN, Vallat A, Luptakova L, Yahiaoui B, Cherrad S, Vacher S, Rateb ME, Belbahri L.

Int J Mol Sci. 2019 Aug 16;20(16). pii: E3989. doi: 10.3390/ijms20163989.

13.

Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer.

Perrot-Applanat M, Vacher S, Pimpie C, Chemlali W, Derieux S, Pocard M, Bieche I.

Oncol Lett. 2019 Jul;18(1):674-686. doi: 10.3892/ol.2019.10392. Epub 2019 May 21.

14.

Alteration of splicing factors' expression during liver disease progression: impact on hepatocellular carcinoma outcome.

Wang H, Lekbaby B, Fares N, Augustin J, Attout T, Schnuriger A, Cassard AM, Panasyuk G, Perlemuter G, Bieche I, Vacher S, Selves J, Péron JM, Bancel B, Merle P, Kremsdorf D, Hall J, Chemin I, Soussan P.

Hepatol Int. 2019 Jul;13(4):454-467. doi: 10.1007/s12072-019-09950-7. Epub 2019 May 28.

PMID:
31140152
15.

Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.

Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E.

Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019.

16.

Cortical branched actin determines cell cycle progression.

Molinie N, Rubtsova SN, Fokin A, Visweshwaran SP, Rocques N, Polesskaya A, Schnitzler A, Vacher S, Denisov EV, Tashireva LA, Perelmuter VM, Cherdyntseva NV, Bièche I, Gautreau AM.

Cell Res. 2019 Jun;29(6):432-445. doi: 10.1038/s41422-019-0160-9. Epub 2019 Apr 10.

17.

Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients.

Cabel L, Decraene C, Bieche I, Pierga JY, Bennamoun M, Fuks D, Ferraz JM, Lefevre M, Baulande S, Bernard V, Vacher S, Mariani P, Proudhon C, Bidard FC, Louvet C.

Cancers (Basel). 2019 Mar 21;11(3). pii: E396. doi: 10.3390/cancers11030396.

18.

A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.

Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E.

Int J Cancer. 2019 Oct 1;145(7):1902-1912. doi: 10.1002/ijc.32266. Epub 2019 Apr 4.

PMID:
30859564
19.

Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesis.

Cacheux W, Lièvre A, Richon S, Vacher S, El Alam E, Briaux A, El Botty R, Mariani P, Buecher B, Schnitzler A, Barbazan J, Roman-Roman S, Bièche I, Dangles-Marie V.

Int J Cancer. 2019 Oct 1;145(7):1852-1859. doi: 10.1002/ijc.32178. Epub 2019 Feb 18.

PMID:
30714617
20.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.

21.

Distinct expression profiles and functions of Kindlins in breast cancer.

Azorin P, Bonin F, Moukachar A, Ponceau A, Vacher S, Bièche I, Marangoni E, Fuhrmann L, Vincent-Salomon A, Lidereau R, Driouch K.

J Exp Clin Cancer Res. 2018 Nov 26;37(1):281. doi: 10.1186/s13046-018-0955-4.

22.

High Prevalence of a Hotspot of Noncoding Somatic Mutations in Intron 6 of GPR126 in Bladder Cancer.

Garinet S, Pignot G, Vacher S, Le Goux C, Schnitzler A, Chemlali W, Sirab N, Barry Delongchamps N, Zerbib M, Sibony M, Allory Y, Damotte D, Bieche I.

Mol Cancer Res. 2019 Feb;17(2):469-475. doi: 10.1158/1541-7786.MCR-18-0363. Epub 2018 Nov 6.

23.

VOPP1 promotes breast tumorigenesis by interacting with the tumor suppressor WWOX.

Bonin F, Taouis K, Azorin P, Petitalot A, Tariq Z, Nola S, Bouteille N, Tury S, Vacher S, Bièche I, Rais KA, Pierron G, Fuhrmann L, Vincent-Salomon A, Formstecher E, Camonis J, Lidereau R, Lallemand F, Driouch K.

BMC Biol. 2018 Oct 2;16(1):109. doi: 10.1186/s12915-018-0576-6.

24.

Emergence of boscalid-resistant strains of Erysiphe necator in French vineyards.

Cherrad S, Charnay A, Hernandez C, Steva H, Belbahri L, Vacher S.

Microbiol Res. 2018 Nov;216:79-84. doi: 10.1016/j.micres.2018.08.007. Epub 2018 Aug 11.

25.

MT1-MMP targeting to endolysosomes is mediated by upregulation of flotillins.

Planchon D, Rios Morris E, Genest M, Comunale F, Vacher S, Bièche I, Denisov EV, Tashireva LA, Perelmuter VM, Linder S, Chavrier P, Bodin S, Gauthier-Rouvière C.

J Cell Sci. 2018 Sep 5;131(17). pii: jcs218925. doi: 10.1242/jcs.218925.

26.

Targeted next-generation sequencing identifies clinically relevant somatic mutations in a large cohort of inflammatory breast cancer.

Liang X, Vacher S, Boulai A, Bernard V, Baulande S, Bohec M, Bièche I, Lerebours F, Callens C.

Breast Cancer Res. 2018 Aug 7;20(1):88. doi: 10.1186/s13058-018-1007-x.

27.

Medullary Breast Carcinoma, a Triple-Negative Breast Cancer Associated with BCLG Overexpression.

Romero P, Benhamo V, Deniziaut G, Fuhrmann L, Berger F, Manié E, Bhalshankar J, Vacher S, Laurent C, Marangoni E, Gruel N, MacGrogan G, Rouzier R, Delattre O, Popova T, Reyal F, Stern MH, Stoppa-Lyonnet D, Marchiò C, Bièche I, Vincent-Salomon A.

Am J Pathol. 2018 Oct;188(10):2378-2391. doi: 10.1016/j.ajpath.2018.06.021. Epub 2018 Aug 1.

28.

Coronin 1C promotes triple-negative breast cancer invasiveness through regulation of MT1-MMP traffic and invadopodia function.

Castagnino A, Castro-Castro A, Irondelle M, Guichard A, Lodillinsky C, Fuhrmann L, Vacher S, Agüera-González S, Zagryazhskaya-Masson A, Romao M, El Kesrouani C, Noegel AA, Dubois T, Raposo G, Bear JE, Clemen CS, Vincent-Salomon A, Bièche I, Chavrier P.

Oncogene. 2018 Dec;37(50):6425-6441. doi: 10.1038/s41388-018-0422-x. Epub 2018 Jul 31.

PMID:
30065298
29.

Prognostic Impact of Residual HPV ctDNA Detection after Chemoradiotherapy for Anal Squamous Cell Carcinoma.

Cabel L, Jeannot E, Bieche I, Vacher S, Callens C, Bazire L, Morel A, Bernard-Tessier A, Chemlali W, Schnitzler A, Lièvre A, Otz J, Minsat M, Vincent-Salomon A, Pierga JY, Buecher B, Mariani P, Proudhon C, Bidard FC, Cacheux W.

Clin Cancer Res. 2018 Nov 15;24(22):5767-5771. doi: 10.1158/1078-0432.CCR-18-0922. Epub 2018 Jul 27.

30.

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition.

El Botty R, Coussy F, Hatem R, Assayag F, Chateau-Joubert S, Servely JL, Leboucher S, Fouillade C, Vacher S, Ouine B, Cartier A, de Koning L, Cottu P, Bièche I, Marangoni E.

Oncotarget. 2018 Jul 3;9(51):29587-29600. doi: 10.18632/oncotarget.25640. eCollection 2018 Jul 3.

31.

ETV4 transcription factor and MMP13 metalloprotease are interplaying actors of breast tumorigenesis.

Dumortier M, Ladam F, Damour I, Vacher S, Bièche I, Marchand N, de Launoit Y, Tulasne D, Chotteau-Lelièvre A.

Breast Cancer Res. 2018 Jul 11;20(1):73. doi: 10.1186/s13058-018-0992-0.

32.

The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.

Tury S, Assayag F, Bonin F, Chateau-Joubert S, Servely JL, Vacher S, Becette V, Caly M, Rapinat A, Gentien D, de la Grange P, Schnitzler A, Lallemand F, Marangoni E, Bièche I, Callens C.

J Pathol. 2018 Sep;246(1):103-114. doi: 10.1002/path.5104. Epub 2018 Aug 7.

PMID:
29876931
33.

The trimeric coiled-coil HSBP1 protein promotes WASH complex assembly at centrosomes.

Visweshwaran SP, Thomason PA, Guerois R, Vacher S, Denisov EV, Tashireva LA, Lomakina ME, Lazennec-Schurdevin C, Lakisic G, Lilla S, Molinie N, Henriot V, Mechulam Y, Alexandrova AY, Cherdyntseva NV, Bièche I, Schmitt E, Insall RH, Gautreau A.

EMBO J. 2018 Jul 2;37(13). pii: e97706. doi: 10.15252/embj.201797706. Epub 2018 May 29.

34.

Array comparative genomic hybridization identifies high level of PI3K/Akt/mTOR pathway alterations in anal cancer recurrences.

Cacheux W, Tsantoulis P, Briaux A, Vacher S, Mariani P, Richard-Molard M, Buecher B, Richon S, Jeannot E, Lazartigues J, Rouleau E, Mariani O, El Alam E, Cros J, Roman-Roman S, Mitry E, Girard E, Dangles-Marie V, Lièvre A, Bièche I.

Cancer Med. 2018 May 26. doi: 10.1002/cam4.1533. [Epub ahead of print]

35.

PKD1 is a potential biomarker and therapeutic target in triple-negative breast cancer.

Spasojevic C, Marangoni E, Vacher S, Assayag F, Meseure D, Château-Joubert S, Humbert M, Karam M, Ricort JM, Auclair C, Regairaz M, Bièche I.

Oncotarget. 2018 May 1;9(33):23208-23219. doi: 10.18632/oncotarget.25292. eCollection 2018 May 1.

36.

Involvement of the FOXO6 transcriptional factor in breast carcinogenesis.

Lallemand F, Petitalot A, Vacher S, de Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla-Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM.

Oncotarget. 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779. eCollection 2018 Jan 26.

37.

Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers.

Marangoni E, Laurent C, Coussy F, El-Botty R, Château-Joubert S, Servely JL, de Plater L, Assayag F, Dahmani A, Montaudon E, Nemati F, Fleury J, Vacher S, Gentien D, Rapinat A, Foidart P, Sounni NE, Noel A, Vincent-Salomon A, Lae M, Decaudin D, Roman-Roman S, Bièche I, Piccart M, Reyal F.

Clin Cancer Res. 2018 Jun 1;24(11):2605-2615. doi: 10.1158/1078-0432.CCR-17-3490. Epub 2018 Feb 20.

38.

Exome sequencing reveals aberrant signalling pathways as hallmark of treatment-naive anal squamous cell carcinoma.

Cacheux W, Dangles-Marie V, Rouleau E, Lazartigues J, Girard E, Briaux A, Mariani P, Richon S, Vacher S, Buecher B, Richard-Molard M, Jeannot E, Servant N, Farkhondeh F, Mariani O, Rio-Frio T, Roman-Roman S, Mitry E, Bieche I, Lièvre A.

Oncotarget. 2017 Dec 8;9(1):464-476. doi: 10.18632/oncotarget.23066. eCollection 2018 Jan 2.

39.

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.

Dubot C, Bernard V, Sablin MP, Vacher S, Chemlali W, Schnitzler A, Pierron G, Ait Rais K, Bessoltane N, Jeannot E, Klijanienko J, Mariani O, Jouffroy T, Calugaru V, Hoffmann C, Lesnik M, Badois N, Berger F, Le Tourneau C, Kamal M, Bieche I.

Eur J Cancer. 2018 Mar;91:47-55. doi: 10.1016/j.ejca.2017.12.016. Epub 2018 Jan 11.

PMID:
29331751
40.

High AHR expression in breast tumors correlates with expression of genes from several signaling pathways namely inflammation and endogenous tryptophan metabolism.

Vacher S, Castagnet P, Chemlali W, Lallemand F, Meseure D, Pocard M, Bieche I, Perrot-Applanat M.

PLoS One. 2018 Jan 10;13(1):e0190619. doi: 10.1371/journal.pone.0190619. eCollection 2018.

41.

mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer.

Le Goux C, Vacher S, Pignot G, Sibony M, Barry Delongchamps N, Terris B, Piaggio E, Zerbib M, Damotte D, Bieche I.

Oncoimmunology. 2017 Aug 14;6(11):e1358330. doi: 10.1080/2162402X.2017.1358330. eCollection 2017.

42.

Comparative Genomics of Bacillus amyloliquefaciens Strains Reveals a Core Genome with Traits for Habitat Adaptation and a Secondary Metabolites Rich Accessory Genome.

Belbahri L, Chenari Bouket A, Rekik I, Alenezi FN, Vallat A, Luptakova L, Petrovova E, Oszako T, Cherrad S, Vacher S, Rateb ME.

Front Microbiol. 2017 Aug 3;8:1438. doi: 10.3389/fmicb.2017.01438. eCollection 2017.

43.

Inactivation of the Kinase Domain of CDK10 Prevents Tumor Growth in a Preclinical Model of Colorectal Cancer, and Is Accompanied by Downregulation of Bcl-2.

Weiswald LB, Hasan MR, Wong JCT, Pasiliao CC, Rahman M, Ren J, Yin Y, Gusscott S, Vacher S, Weng AP, Kennecke HF, Bièche I, Schaeffer DF, Yapp DT, Tai IT.

Mol Cancer Ther. 2017 Oct;16(10):2292-2303. doi: 10.1158/1535-7163.MCT-16-0666. Epub 2017 Jun 29.

44.

Exposure of marine mussels to diclofenac: modulation of prostaglandin biosynthesis.

Courant F, Arpin-Pont L, Bonnefille B, Vacher S, Picot-Groz M, Gomez E, Fenet H.

Environ Sci Pollut Res Int. 2018 Mar;25(7):6087-6094. doi: 10.1007/s11356-017-9228-6. Epub 2017 May 21.

PMID:
28528506
45.

Clinical value of R-spondins in triple-negative and metaplastic breast cancers.

Coussy F, Lallemand F, Vacher S, Schnitzler A, Chemlali W, Caly M, Nicolas A, Richon S, Meseure D, El Botty R, De-Plater L, Fuhrmann L, Dubois T, Roman-Roman S, Dangles-Marie V, Marangoni E, Bièche I.

Br J Cancer. 2017 Jun 6;116(12):1595-1603. doi: 10.1038/bjc.2017.131. Epub 2017 May 4.

46.

Correlation between messenger RNA expression and protein expression of immune checkpoint-associated molecules in bladder urothelial carcinoma: A retrospective study.

Le Goux C, Damotte D, Vacher S, Sibony M, Delongchamps NB, Schnitzler A, Terris B, Zerbib M, Bieche I, Pignot G.

Urol Oncol. 2017 May;35(5):257-263. doi: 10.1016/j.urolonc.2017.01.014. Epub 2017 Mar 11.

PMID:
28291636
47.

Alterations in the balance of tubulin glycylation and glutamylation in photoreceptors leads to retinal degeneration.

Bosch Grau M, Masson C, Gadadhar S, Rocha C, Tort O, Marques Sousa P, Vacher S, Bieche I, Janke C.

J Cell Sci. 2017 Mar 1;130(5):938-949. doi: 10.1242/jcs.199091. Epub 2017 Jan 19. Erratum in: J Cell Sci. 2020 Feb 10;133(3):.

48.

Combination of COX-2 expression and PIK3CA mutation as prognostic and predictive markers for celecoxib treatment in breast cancer.

Tury S, Becette V, Assayag F, Vacher S, Benoist C, Kamal M, Marangoni E, Bièche I, Lerebours F, Callens C.

Oncotarget. 2016 Dec 20;7(51):85124-85141. doi: 10.18632/oncotarget.13200.

49.

Gain-of-function Prolactin Receptor Variants Are Not Associated With Breast Cancer and Multiple Fibroadenoma Risk.

Chakhtoura Z, Laki F, Bernadet M, Cherifi I, Chiche A, Pigat N, Bernichtein S, Courtillot C, Boutillon F, Bièche I, Vacher S, Tanguy ML, Bissery A, Grouthier V, Camparo P, Foretz M, Do Cruzeiro M, Pierre R, Rakotozafy F, Tichet J, Tejedor I, Guidotti JE, Sigal-Zafrani B, Goffin V, Touraine P.

J Clin Endocrinol Metab. 2016 Nov;101(11):4449-4460. Epub 2016 Aug 30.

PMID:
27575941
50.

MED12 mutations in breast phyllodes tumors: evidence of temporal tumoral heterogeneity and identification of associated critical signaling pathways.

Laé M, Gardrat S, Rondeau S, Richardot C, Caly M, Chemlali W, Vacher S, Couturier J, Mariani O, Terrier P, Bièche I.

Oncotarget. 2016 Dec 20;7(51):84428-84438. doi: 10.18632/oncotarget.12991.

Supplemental Content

Loading ...
Support Center